Table 1.

Clinicopathological characteristics of 20 patients with hepatocellular carcinoma (HCC)

	HCC arising from NAFLD (n = 10)	HCC arising from HCV‐infected liver (n = 10)	P‐value
Sex
Male	9	7
Female	1	3	n.s.
Age, years
Median (range)	72 (68–90)	70 (57–78)	n.s.
BMI	25.0 (20.4–27.4)	20.9 (19.1–27.4)	0.014
Blood examination
T. Bil, mg/dL (range)	0.75 (0.4–1.8)	0.85 (0.4–1.7)	n.s.
AST, IU/mL (range)	35 (18–72)	42 (22–72)	n.s.
ALT, IU/mL (range)	36.5 (13–79)	29.5 (13–82)	n.s.
Alb, mg/dL (range)	4.25 (3.1–4.8)	4.15 (3.8–4.7)	n.s.
PT (%) (range)	95.5 (73–125)	90 (78–132)	n.s.
Alpha‐fetoprotein, ng/mL
Median (range)	4 (1–1074)	6.5 (4–119 665)	n.s.
PIVKA‐II, mAU/mL
Median (range)	277 (13–15 905)	37.5 (20–2130)	n.s.
Tumor size, cm
Median (range)	3.8 (1.7–14)	2.9 (1.5–8.5)	n.s.
Tumor number
Solitary	7	5
Multiple	3	5	n.s.
Stage (UICC)
I	6	5
II	4	3
IIIa	0	2	n.s.

Alb, albumin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; HCV, hepatitis C virus; NAFLD, non‐alcoholic fatty liver disease; n.s., not significant; PIVKA‐II, protein induced by vitamin K absence‐II; PT, prothrombin time.